GSK: How much could the Zantac lawsuits cost? June 3, 2024 Last month, Shore Capital analysts estimated that up to $30bn (£24bn) for litigation was already priced into GSK’s shares.
GSK raises £1.25bn as it offloads final stake in Haleon May 17, 2024 The move separates the companies after a carve-up twoo years ago that saw GSK spin off and float its consumer arm as Haleon, amid fears the division was weighing on the growth of its dedicated healthcare business.
Haleon posts healthy first quarter update after UK job cuts May 1, 2024 Revenue at Haleon was up in the first quarter despite its announcement yesterday that it would cut over 400 jobs in the UK, as the consumer healthcare firm posted a quarterly update in line with expectations.
GSK raises 2024 guidance after strong vaccine sales May 1, 2024 In its first quarter, British company GSK said sales rose 10 per cent to £7.4bn but total operating profit fell 18 per cent to £1.49bn.
US regulator accepts GSK’s application to expand treatment of cancer drug April 24, 2024 The treatment, Jemperli, will now be classed as being able to help all adult patients with primary advanced or recurrent endometrial cancer. It is used alongside chemotherapy.
Covid-19 anniversary: How have GSK and Astrazeneca fared since? March 23, 2024 The Covid-19 pandemic also ignited interest in the pharmaceutical sector. Even before the UK went into lockdown, the sector was looking for ways to fight the virus.
GSK: Cancer claims plague pharma giant as it settles another Zantac case February 29, 2024 GSK has reached another confidential settlement in a Californian lawsuit that had alleged its best-selling indigestion drug, Zantac, was carcinogenic.
Haleon reports single-digit growth in revenue after year of disposals February 29, 2024 Its revenue went up by four per cent from £10.8bn reported in 2022, as the company's adjusted operating profit had a healthy growth of 10.4 per cent, at constant currency to £2.5bn.
GSK reports robust results from latest trial with injectable HIV treatment February 21, 2024 GSK has today reported favourable findings from the Latitude phase III study of its long-acting injectable antiretroviral treatment (ART) for HIV. The study was conducted by Viiv Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders. The company said that an interim analysis of the Latitude [...]
GSK snaps up potential asthma treatment gamechanger in £800m deal February 15, 2024 GSK has completed the acquisition of Aiolos Bio, a company working on treatments for respiratory and inflammatory conditions.